Navigation Links
FundRx Announces Investment in NeuroOne Inc.
Date:3/15/2017

FundRx Inc., an early stage healthcare venture capital firm, today announced that it has invested in NeuroOne Inc., a next generation, platform technology company focused on developing advanced neuromonitoring and neuromodulating products. FundRx participated in a $1.2 million seed round which will be used to accelerate NeuroOne’s lead product, a neurodiagnostic solution for the treatment of epilepsy. NeuroOne’s core technology was developed in partnership with the Mayo Clinic and the University of Wisconsin.

“NeuroOne’s technology platform will add significant value both for payors and patients specifically in the way we manage treatments for epilepsy, Parkinson’s disease, and other neurological disorders. This is an example where innovation in other fields, such as semiconductors, have a direct impact on improving healthcare once the human science catches up,” said Zeshan Muhammedi, CEO at FundRx.

FundRx’s network of neurologists, neurosurgeons and diagnostic experts evaluated NeuroOne through its Peer Review Council process. This Council is an integral part of the FundRx diligence process as it helps evaluate a company’s core scientific merits directly by a large pool of clinical experts while verifying the true business market with industry members.

“Most investors are strictly capital providers. FundRx is different. Not only did they help us secure the capital we need to further develop our lead product, they introduced us to key physicians who helped validate our technology and delivered us valuable market research which we have incorporated into our business strategy and plan for NeuroOne. FundRx has been a true partner and we are honored to be working with them as we enter this next stage of growth,” said Dave Rosa, CEO of NeuroOne.

Muhammedi continued, “In just a short period of time, we have been approached by numerous experts on our platform seeking to work with the NeuroOne team. This further validates the potential of NeuroOne’s technology and its impact on the neurology industry.”

FundRx Background
FundRx’s mission is to accelerate the development of early stage healthcare companies. The firm has built a technology enabled platform which enables companies to access capital but also the diligence, resources, and connections they need to build and grow their businesses. FundRx’s platform consists of 2,600 physicians, scientists, and industry experts from some of the world’s leading institutions including Harvard University, Mt. Sinai Hospital, Stanford University and Tufts University.

To date, FundRx has funded 11 healthcare start-ups including EpiBone, a revolutionary bone reconstruction company; Saferide, an on-demand non-emergency transportation company; Soundbite Medical Solutions, a cardiovascular medical technology company developing a proprietary shockwave technology to address significant unmet clinical needs in interventional cardiology; and SnapMD, a cloud-based virtual care management telemedicine company. FundRx was founded in 2015 by Zeshan Muhammedi, Gurdane Bhutani and Justin Martin.

About NeuroOne
NeuroOne’s mission is to provide comprehensive neuromodulation cEEG monitoring and treatment solutions for patients suffering from epilepsy and other nerve related disorders that result in superior patient outcomes with reduced overall costs. The company is headquartered in Minnetonka, Minnesota and is currently pursuing a near-term FDA approval for its lead product through the 510(k) submission process. For more information visit, http://www.neurooneinc.com.

About FundRx
Founded in 2015 and based in New York, FundRx is an early stage healthcare venture capital firm. The firm seeks to fund, support and build high impact start-up companies pursuing novel research and new models of care. FundRx works closely with physicians, scientists, and industry partners to ensure quality companies receive the resources they need to move their innovations from the lab to the clinic. More information is available at http://www.fundrx.com.

# # #

Contact:
Zeshan Muhammedi
CEO
FundRx
646-751-7634
zeshan(at)fundrx(dot)co

Read the full story at http://www.prweb.com/releases/2017/03/prweb14147121.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. PMG Research Announces Clinical Trial Community with Smart Patients
2. Cellecta, Inc. Announces Upcoming Presentations at the American Association for Cancer Research 2017 Annual Meeting
3. Eurofins Genomics US Announces Commercial Launch of Next Generation DNA Synthesis Service
4. OncoSec Announces First Technology Access Program Agreement with Inhibrx
5. Dove Press Announces Sponsorship of Nanomedicine Academy of Minority Serving Institutions at Northeastern University
6. Northwest Kidney Centers Announces Intention to Grant $15 Million to Jumpstart UW Medicines Center for Dialysis Innovation
7. Integrated Service Solutions, Inc. Announces Expanded Scope of Accreditation by A2LA
8. Aethlon Medical Announces The Conclusion Of Hemopurifier Clinical Study
9. ClinCapture Announces Open House to Celebrate Launch of New EDC Product
10. Acumed LLC Announces Appointment of Sharon Wolfington as President and Chief Executive Officer
11. Rosalind Franklin University announces construction of new Innovation and Research Park
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... ... Bacterial biofilms, surface adherent communities of bacteria that are encased in a ... and catheter infections to gum disease and the rejection of medical implants. Though ... year, there is currently a paucity of means for preventing their formation or treating ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... it is exhibiting in booth B2 at the Association for Pathology Informatics ... , In addition to demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. ... 2017 at the Prince Of Wales Private Hospital. The procedure was performed on ... The patient failed conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic ...
(Date:5/18/2017)... Massachusetts (PRWEB) , ... May 17, 2017 , ... ... company specializing in medical device compliance and commercialization, has just released version 9.0 ... of work into this latest version of Cockpit,” says David Cronin, CEO of ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/23/2017)... Mar. 23, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 8.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):